GENERATION OF CLINICALLY COMPLIANT hESC/RPE CELLS FOR THERAPY OF EYE DISEASES
With the use of pioneering genetic technologies and functional assays, Dr. Fredrik Lanner is among the first to attempt to modify the genes of human embryos to learn more about pluripotency and early embryonic development. In addition, his research group is exploring the treatment of age-related macular degeneration using hESC derived retinal pigmented epithelial (RPE) cells. A GMP bank of clinically compliant, HLA-matched human ESC/RPE cells is currently being established.
STEM CELL-BASED TREATMENT FOR PARKINSON'S DISEASE
Professor Malin Parmar studies cell fate specification in the developing brain and in human neural progenitor cells by direct, efficient and controlled differentiation of human stem cells into subtype-specific neurons. Her research has made it possible to efficiently and reproducibly produce an hESC-derived dopaminergic progenitor cell product for a clinical trial for Parkinson’s disease. This is her story!